BC Extra | Jan 22, 2020
Clinical News

BeiGene gearing up for PD-1 competition with Merck, Innovent in 1L squamous NSCLC in China

BeiGene announced Tuesday that tislelizumab met the primary endpoint in a Chinese Phase III trial for first-line squamous non-small cell lung cancer. The readout keeps BeiGene’s PD-1 mAb on track as it vies with Innovent’s...
BC Extra | Jan 7, 2020
Company News

BeiGene looks to carve out niche in China for tislelizumab

As it looks to roll out what will be at least the sixth marketed PD-1 inhibitor in China, BeiGene hopes the therapy’s differentiated efficacy profile and commercial infrastructure will help the company carve a niche...
BC Extra | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

Following the nationwide expansion of China’s pilot program for centralized procurement of generics and off-patent originator drugs, Beijing is adding a second group of 33 drugs and unveiling new rules that could increase the number...
BC Extra | Dec 5, 2019
Company News

Dec. 4 Company Quick Takes: Allakos on the block?; plus Aurinia, Tecentriq, Gatehouse-AZ, Novartis-Amazon, Merck KGaA-Ping An and ICT

Allakos shares jump on report of potential sale Allakos Inc. (NASDAQ:ALLK) declined to comment on a Bloomberg report citing unnamed sources that the company has hired a financial adviser to explore strategic options, including a...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BC Extra | Nov 4, 2019
Clinical News

Halozyme to focus on Enhanze partnering after Phase III oncology miss

With the failure of Halozyme's lead cancer program in a Phase III trial, the company intends to exit the oncology R&D field entirely and focus on deriving partner revenue from its subcutaneous drug delivery technology...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...
BC Extra | Sep 30, 2019
Clinical News

Phase II data for G1’s trilaciclib raises questions about its uptake potential in TNBC

G1 showed trilaciclib led to a significant reduction in the risk of death for metastatic triple-negative breast cancer, but a shifting treatment landscape that includes checkpoint inhibitors could mean an uncertain commercial and regulatory path...
BC Extra | Sep 26, 2019
Clinical News

Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

Despite shedding over $200 million from its market cap Thursday after reporting response data from the triple-negative breast cancer cohort of its bempegaldesleukin/Opdivo nivolumab combination trial, Nektar is looking ahead to the next set of...
BC Extra | Sep 9, 2019
Company News

BeiGene pushes back on short seller report

BeiGene refuted claims by short seller J Capital that the company has reported “fake sales” of its cancer portfolio from Celgene. John Oyler, CEO of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), told BioCentury, “It’s easy to see...
Items per page:
1 - 10 of 424